目的 观察聚乙二醇洛塞那肽联合维格列汀治疗2型糖尿病的临床疗效。方法 回顾性研究以2023年8月—2024年8月新乡市中心医院收治的92例2型糖尿病患者为研究对象，根据治疗方案不同将患者分为对照组和治疗组，每组各46例。对照组给予口服维格列汀片，50 mg/次，2次/d。治疗组患者在对照组治疗基础上联合皮下注射聚乙二醇洛塞那肽注射液，0.2 mg/次，1次/周。两组患者均连续治疗12周。观察两组临床疗效，比较两组治疗前后一般情况、血糖相关指标、胰岛功能相关指标。结果 治疗后，治疗组总有效率是93.48%，显著高于对照组的76.09%（P＜0.05）。治疗后两组身体质量指数（BMI）、内脏脂肪、体质量、腰臀比值均较治疗前下降（P＜0.05），且治疗组BMI、内脏脂肪、体质量、腰臀比低于对照组（P＜0.05）。治疗后两组空腹血糖（FBG）、餐后2 h血糖（2 h FBG）、糖化血红蛋白（HbA1c）较同组治疗前显著降低（P＜0.05）；治疗后，治疗组FBG、2 h FBG及HbA1c低于对照组（P＜0.05）。治疗后，两组空腹胰岛素（FINS）、胰岛β细胞功能指数（HOMA-β）水平较同组治疗前显著升高，胰岛素抵抗指数（HOMA-IR）显著下降（P＜0.05）；治疗后，治疗组FINS、HOMA-β高于对照组，HOMA-IR低于对照组（P＜0.05）。结论 聚乙二醇洛塞那肽联合维格列汀可显著提高2型糖尿病患者的治疗效果，改善患者BMI、腰臀比、体质量、内脏脂肪及糖脂代谢指标，促进胰岛β细胞功能恢复，且药物安全性良好。

Objective To observe the clinical efficacy of polyethylene glycol losenatide combined with vilagliptin in treatment of type 2 diabetes. Methods A retrospective study took 92 patients with type 2 diabetes admitted to Xinxiang Central Hospital from August 2023 to August 2024 as the research subjects. The patients were divided into control group and treatment group according to different treatment plans, with 46 cases in each group. Patients in control group were po administered Vildagliptin Tables, 50 mg/time, twice daily. Patients in treatment group were combined with subcutaneous injection of Polyethylene Glycol Loxenatide Injection, 0.2 mg each time, once a week on the basis of treatment in control group. Both groups of patients were treated continuously for 12 weeks. The clinical efficacy of two groups was observed, and the general conditions, blood glucose related indicators, and pancreatic islet function-related indicators of two groups before and after treatment were compared. Results After treatment, the total effective rate of the treatment group was 93.48%, significantly higher than that of the control group (76.09%, P < 0.05). After treatment, BMI, visceral fat, body weight, and waist-hip ratio of both groups decreased compared with those before treatment (P < 0.05), and the BMI, visceral fat, body weight, and waist-hip ratio of treatment group were lower than those of control group (P < 0.05). After treatment, FBG, 2 h FBG, and HbA1c in both groups were significantly lower than those before treatment in the same group (P < 0.05). After treatment, the FBG, 2 h FBG, and HbA1c in treatment group were lower than those in control group (P < 0.05). After treatment, the levels of FINS and HOMA-β in both groups were significantly increased compared with those before treatment in the same group, but HOMA-IR was significantly decreased (P < 0.05). After treatment, FINS and HOMA-β in treatment group were higher than those in control group, but HOMA-IR was lower than that in control group (P < 0.05). Conclusion Polyethylene glycol losenatide combined with vilagliptin can significantly improve the therapeutic effect of patients with type 2 diabetes, enhance their BMI, waist-hip ratio, body weight, visceral fat and glycolipid metabolism indicators, promote the recovery of pancreatic β cell function, and the drug has good safety.

R977

河南省医学科技攻关计划项目（LHGJ20221003）